North America Contraceptives Market

North America Contraceptives Market Size (2023 to 2028)

As per our report, the Contraceptives Market size in North America was worth USD 7.80 billion in 2023 and estimated to reach USD 10.64 billion by the end of 2028, registering a CAGR of 6.40% during the forecast period.

The growing awareness about family planning among the population of North American countries is one of the key factors propelling the growth of the contraceptives market in North America. The governments of North American countries have implemented several programs focused on family planning, aiming to provide medical, educational and social activities that equip individuals, including minors, with the knowledge to make informed decisions about the number of children they desire. To facilitate the family planning process, the market offers a range of contraceptive methods. Oral contraceptive pills and female sterilization rank as the most commonly utilized contraceptive or birth control techniques in the U.S.

The growing prevalence of sexually transmitted infections (STIs) and increasing unintended pregnancies among women further boost the growth of the contraceptives market in the North American region. In recent years, couples have increasingly relied on condoms as a means to prevent pregnancies, thereby contributing to the market's expansion. Condom usage has been shown to effectively reduce the risk of contracting sexually transmitted infections, including chronic conditions like HIV/AIDS. Approximately 33 million Americans have utilized condoms as their preferred contraceptive method. Unintended pregnancies, characterized as undesired or unplanned, have witnessed an increase, prompting the younger generation to adopt various contraceptive methods as preventive measures.

The growing number of manufacturing activities of a wide range of contraceptive devices drive regional market growth. Researchers are dedicating their efforts to conducting extensive clinical trials to minimize complications and side effects associated with contraceptive methods, thus catering to the market's demand. Manufacturers are prioritizing the provision of high-quality and cost-effective devices and drugs to augment market demand. Moreover, the market is benefiting from increased investments by public and private healthcare organizations, a surge in device approvals, and amplified government support. These factors collectively contribute to the rising demand for contraceptives in the region.

The high cost associated with certain contraceptive surgeries primarily hamper the market growth. Factors such as lack of awareness, limited social acceptance, availability of alternative contraceptive methods and inadequate availability of contraceptive devices and drugs further impede the growth of the North American contraceptives market. Complications and side effects include nausea, vomiting, headache, sore breasts, and vaginal infections arising from contraceptive treatments and drugs show a negative impact on the market's growth rate in this region. Notably, among a subset of the female population, the use of specific contraceptive devices and drugs carries the risk of post-usage bleeding. These factors collectively pose hurdles to the market's growth prospects.

This research report on the North American Contraceptives Market has been segmented & sub-segmented into the following categories:

By Drug Type: 

• Contraceptive Pills
• Topical Contraceptives
• Contraceptive Injectable
• Others (Contraceptive Gels, Jellies, and Creams)

By Medical Devices: 

• Male Contraceptive Devices (Condoms)
• Female Contraceptive Devices
  • Female Condoms
  • Intrauterine Devices
    • Hormonal IUD’s
    • Copper IUD’s
• Contraceptive Sponges
• Contraceptive Diaphragms
• Subdermal Contraceptive Implants
• Contraceptive Patches
• Non-Surgical Permanent Contraceptive Devices

By End User: 

• Hospitals
• Home Care
• Clinics
• Ambulatory Surgical Centres

By Country: 

• The U.S.
• Canada
• Rest of North America

North America accounted for the major share of the worldwide market in 2023 and the domination of the region in the global market is anticipated to continue during the forecast period. The contraceptives market in the North American region benefits from extensive advertising campaigns aimed at promoting contraceptive methods to a large audience, the implementation of social awareness programs, increasing literacy rates and growing awareness about contraceptive methods among the population.

The U.S. contraceptives market is expected to hold the leading share of the North American market during the forecast period owing to the presence of numerous manufacturing facilities and the increasing number of pharmaceutical companies. The availability of a wide range of contraceptive products and devices through both online and offline channels including e-commerce platforms and pharmacies further drives the growth of the U.S. market.

Canada is a noteworthy regional market for contraceptives in North America and is predicted to register a healthy CAGR during the forecast period. Health Canada plays a crucial role in ensuring the safety and efficacy of contraceptive methods and medications by rigorously approving them to mitigate potential side effects in Canada. The establishment of clinical trial centers, increasing partnerships between organizations, and a rising number of mergers and acquisitions drive innovation and Canadian market growth.

Some of the key players that are dominating the North America contraceptives market are Bayer HealthCare AG, Teva Pharmaceutical Industries Limited, Medisafe Distribution Inc, Pace Pharmaceuticals Inc., Medicines360, Church & Dwight, Co., Inc., Actavis, Inc., CooperSurgical, Inc., Merck & Co., Inc., Reckitt Benckiser plc, Mayer Laboratories, Inc., and Pfizer, Inc.